Based on the Suven Pharmaceuticals Limited stock forecast from 2 analysts, the average analyst target price for Suven Pharmaceuticals Limited is INR 1,402.50 over the next 12 months. Suven Pharmaceuticals Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Suven Pharmaceuticals Limited is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Suven Pharmaceuticals Limited’s stock price was INR 1,058.20. Suven Pharmaceuticals Limited’s stock price has changed by -0.19% over the past week, -10.69% over the past month and +63.21% over the last year.
No recent analyst target price found for Suven Pharmaceuticals Limited
No recent average analyst rating found for Suven Pharmaceuticals Limited
Company Overview Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is based in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited. Read Less
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible ...Read More
Frequently Asked Questions About Suven Pharmaceuticals Limited (SUVENPHAR:NSE) Stock
Based on ratings from 2 analysts Suven Pharmaceuticals Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on SUVENPHAR:NSE's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SUVENPHAR:NSE is INR 1,402.50 over the next 12 months. The maximum analyst target price is INR 1405 while the minimum anlayst target price is INR 1400.
SUVENPHAR:NSE stock's Price/Earning ratio is 98.61.
Our analysis grades SUVENPHAR:NSE stock's Price / Earning ratio at F. This means that SUVENPHAR:NSE stock's Price/Earning ratio is above 87% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this SUVENPHAR:NSE may be a overvalued for its sector.
The last closing price of SUVENPHAR:NSE's stock was INR 1,058.20.
The most recent market capitalization for SUVENPHAR:NSE is INR 274.37B.
Based on targets from 2 analysts, the average taret price for SUVENPHAR:NSE is projected at INR 1,402.50 over the next 12 months.
This means that SUVENPHAR:NSE's stock price may go up by +32.54% over the next 12 months.
We can't find any ETFs which contains Suven Pharmaceuticals Limited's stock.
As per our most recent records Suven Pharmaceuticals Limited has 0 Employees.
Suven Pharmaceuticals Limited's registered address is 202, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad, India, 500081.
You can get more information about it from Suven Pharmaceuticals Limited's website at https://www.cohance.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Suven Pharmaceuticals Limited (SUVENPHAR:NSE) Stock
Based on ratings from 2 analysts Suven Pharmaceuticals Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on SUVENPHAR:NSE's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for SUVENPHAR:NSE is INR 1,402.50 over the next 12 months. The maximum analyst target price is INR 1405 while the minimum anlayst target price is INR 1400.
SUVENPHAR:NSE stock's Price/Earning ratio is 98.61.
Our analysis grades SUVENPHAR:NSE stock's Price / Earning ratio at F. This means that SUVENPHAR:NSE stock's Price/Earning ratio is above 87% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this SUVENPHAR:NSE may be a overvalued for its sector.
The last closing price of SUVENPHAR:NSE's stock was INR 1,058.20.
The most recent market capitalization for SUVENPHAR:NSE is INR 274.37B.
Based on targets from 2 analysts, the average taret price for SUVENPHAR:NSE is projected at INR 1,402.50 over the next 12 months.
This means that SUVENPHAR:NSE's stock price may go up by +32.54% over the next 12 months.
We can't find any ETFs which contains Suven Pharmaceuticals Limited's stock.
As per our most recent records Suven Pharmaceuticals Limited has 0 Employees.
Suven Pharmaceuticals Limited's registered address is 202, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad, India, 500081.
You can get more information about it from Suven Pharmaceuticals Limited's website at https://www.cohance.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SUVENPHAR:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
